0001209191-20-027885.txt : 20200508 0001209191-20-027885.hdr.sgml : 20200508 20200508161910 ACCESSION NUMBER: 0001209191-20-027885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200506 FILED AS OF DATE: 20200508 DATE AS OF CHANGE: 20200508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kewalramani Reshma CENTRAL INDEX KEY: 0001735944 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20860839 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-06 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001735944 Kewalramani Reshma C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2020-05-06 4 M 0 1564 187.53 A 28190 D Common Stock 2020-05-06 4 M 0 510 155.57 A 28700 D Common Stock 2020-05-06 4 S 0 416 270.35 D 28284 D Common Stock 2020-05-06 4 S 0 300 271.92 D 27984 D Common Stock 2020-05-06 4 S 0 360 272.77 D 27624 D Common Stock 2020-05-06 4 S 0 864 274.04 D 26760 D Common Stock 2020-05-06 4 S 0 134 275.17 D 26626 D Stock Option (Right to Buy) 187.53 2020-05-06 4 M 0 1564 0.00 D 2029-02-05 Common Stock 1564 17206 D Stock Option (Right to Buy) 155.57 2020-05-06 4 M 0 510 0.00 D 2028-02-05 Common Stock 510 3567 D Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $270.35 (range $269.87 to $270.75). Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $271.92 (range $271.33 to $272.17). Open market sales reported on this line occurred at a weighted average price of $272.77 (range $272.44 to $273.30). Open market sales reported on this line occurred at a weighted average price of $274.04 (range $273.56 to $274.40). Open market sales reported on this line occurred at a weighted average price of $275.17 (range $274.60 to $275.30). The option vests in 16 quarterly installments from 02/06/2019. The option vests in 16 quarterly installments from 02/06/2018. /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-08